US › Healthcare

Phathom Pharmaceuticals Inc (PHAT)

US · Healthcare · Biotechnology

$8.45-5.90%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$58.3M
Revenue YoY
+104.4%
Net profit
$-30.4M
Profit YoY
+67.8%
EPS
$-0.18
EPS estimate
$-0.39
Net margin
-52.1%

EPS came in at -0.18 against a street estimate of -0.39 — a beat of 53.8%.

Key statistics

Market cap
$707.9M
Forward P/E
0.0
P/B
25.37
Book value
$-4.30
EPS (TTM)
$-1.25
52-week high
$18.31
52-week low
$8.03
50-day MA
$10.80
200-day MA
$12.66
Beta
0.49

Analyst view

Analysts rate Phathom Pharmaceuticals Inc a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $23.70.

Shareholding

Insiders
4.73%
Institutions
88.90%

Largest institutional holders

FundStake
Frazier Life Sciences Management, L.P.15.63%
Medicxi Ventures Management (Jersey) Ltd9.36%
Amvescap Plc.5.42%
BlackRock Inc5.09%
Millennium Management LLC5.04%
The Carlyle Group Inc4.38%
Vanguard Group Inc3.98%
Vanguard Capital Management, LLC3.24%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Phathom Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.